Hepatitis C Drug Market 2019 Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments

1
Hepatitis C Drug Market Size, Share Industry
Analysis, By Product (NS5A Inhibitor (Protease
Inhibitors), Fixed-dose Combination, Others), By
Disease Type (Acute Hepatitis C, Chronic
Hepatitis C), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies,
Others) and Regional Forecast, 2019-2026
Buy Now
Sample PDF
Get Discount
Published Date April 2019 Report Format PDF
Region Global Base Year 2018
2
Hepatitis C Drug Market Size, Share Industry
Analysis, By Product (NS5A Inhibitor (Protease
Inhibitors), Fixed-dose Combination, Others), By
Disease Type (Acute Hepatitis C, Chronic
Hepatitis C), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies,
Others) and Regional Forecast, 2019-2026
Report Highlights The global Hepatitis C Drug
market will derive growth impetus from the high
prevalence of hepatitis C across the world.
According to a report published by Fortune
Business Insights, titled Hepatitis C Drug
Global Market Analysis, Insights and Forecast,
2019-2026, the market was valued at US 7,866.6
Mn in 2018. Fortune Business Insights states that
the market is projected to reach US 7,351.7 Mn
by 2026, exhibiting a CAGR of -0.9 in the
forecast period. Hepatitis C is a viral
infection that causes severe damage such as
inflammation of the liver and can spread through
contaminated blood. The advanced stages of
hepatitis C can also lead to liver damage,
thereby creating severe health risks. The
severity of hepatitis C has created a huge
emphasis on the research and development of drugs
associated with the treatment of this disease.
Several new drugs have been launched in recent
times, due to the high prevalence of hepatitis C
across the world. Hepatitis C requires oral
injections and dosages on a weekly basis, and it
also has several side effects that can also lead
to permanent damage.
3
Hepatitis C Drug Market Size, Share Industry
Analysis, By Product (NS5A Inhibitor (Protease
Inhibitors), Fixed-dose Combination, Others), By
Disease Type (Acute Hepatitis C, Chronic
Hepatitis C), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies,
Others) and Regional Forecast, 2019-2026
Increasing Drug Approvals Will Favor Market
Growth The escalating demand for Hepatitis C Drug
has yielded several regulatory approvals for
associated drugs. Fortune Business Insights has
predicted that increasing regulatory approvals
for related drugs and recombinant products will
constitute an increase in the global Hepatitis C
Drug market value in the coming years. The
Hepatitis C Drug industry has witnessed numerous
drug approvals in recent years driven by the
increasing fatality rate of the disease. In April
2019, the United States Food and Drug
Administration passed approval for Mavyret for
the treatment of hepatitis C in pediatric
patients. Huge Hepatitis C Patient Pool Will
Offer Growth Opportunities for the Market in
North America The high prevalence of hepatitis C
has created a need for efficient drugs at low
cost. Fortune Business Insights has identified
increasing hepatitis C incidence as a primary
growth driver. The increased adoption of
Hepatitis C Drug will favor the growth of the
market in North America. Fortune Business
Insights has predicted that the Hepatitis C Drug
market in North America will witness considerable
growth, driven by the high demand for Hepatitis C
Drug. Browse Complete Report Details https//www
.fortunebusinessinsights.com/industry-reports/hepa
titis-c-drug-market-101562
4
Hepatitis C Drug Market Size, Share Industry
Analysis, By Product (NS5A Inhibitor (Protease
Inhibitors), Fixed-dose Combination, Others), By
Disease Type (Acute Hepatitis C, Chronic
Hepatitis C), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies,
Others) and Regional Forecast, 2019-2026
The high prevalence of hepatitis C has created a
need for efficient drugs at low cost. Fortune
Business Insights has identified increasing
hepatitis C incidence as a primary growth driver.
The increased adoption of Hepatitis C Drug will
favor the growth of the market in North America.
Fortune Business Insights has predicted that the
Hepatitis C Drug market in North America will
witness considerable growth, driven by the high
demand for Hepatitis C Drug. Top Players
Mentioned Fortune Business Insights profiles a
few of the companies operating in the Hepatitis C
Drug Market AbbVie Inc. Gilead Sciences,
Inc. Bristol-Myers Squibb Company Janssen
Pharmaceuticals, Inc. Merck Sharp Dohme Corp.
F. Hoffmann-La Roche Ltd Vertex Pharmaceuticals
Incorporated
5
Hepatitis C Drug Market Size, Share Industry
Analysis, By Product (NS5A Inhibitor (Protease
Inhibitors), Fixed-dose Combination, Others), By
Disease Type (Acute Hepatitis C, Chronic
Hepatitis C), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies,
Others) and Regional Forecast, 2019-2026
About Us Fortune Business Insights offers expert
corporate analysis and accurate data, helping
organizations of all sizes make timely decisions.
We tailor innovative solutions for our clients,
assisting them to address challenges distinct to
their businesses. Our goal is to empower our
clients with holistic market intelligence, giving
a granular overview of the market they are
operating in.    Our reports contain a unique mix
of tangible insights and qualitative analysis to
help companies achieve sustainable growth. Our
team of experienced analysts and consultants use
industry-leading research tools and techniques to
compile comprehensive market studies,
interspersed with relevant data.    Phone US 1
424 253 0390 UK 44 2071 939123 APAC 91 744
740 1245 Email sales_at_fortunebusinessinsights.com